脾边缘区淋巴瘤的遗传与表型特征
该研究通过多平台方法分析303例SMZL脾脏样本,识别出两个主要遗传簇:NNK(58%)和DMT(32%),两者生物学特征和生存预后不同,NNK预后更差。同时免疫微环境可分为免疫抑制型(50%)和免疫沉默型(50%),具有不同突变和临床意义。研究提出SMZL的新分类学框架,有助于合理靶向治疗开发。
要点
- SMZL可分为NNK和DMT两个遗传簇,NNK预后更差。
- 免疫微环境分免疫抑制型和免疫沉默型,各占50%。
- 该分类框架有助于SMZL的精准分型和靶向治疗。
核心结论
- SMZL存在两个主要遗传簇NNK和DMT,具有不同生物学和预后。
- 免疫微环境可分为免疫抑制型和免疫沉默型,各占50%,具有不同突变和临床意义。
- 提出的SMZL分类学有助于实现其分类并指导合理靶向治疗开发。
研究设计与样本
- 研究纳入303例SMZL脾脏样本,来自IELSG46多中心国际研究(NCT02945319)。
- 采用多平台方法进行遗传和表型分析,定义自组织特征,并在独立原发肿瘤元数据和基因修饰小鼠模型中验证。
主要发现
- 识别出两个主要遗传簇:NNK(58%病例,涉及NF-κB、NOTCH和KLF2模块)和DMT(32%病例,涉及DNA损伤反应、MAPK和TLR模块)。
- NNK-SMZL与DMT-SMZL在多个基因的遗传畸变以及细胞遗传和免疫遗传特征上不同。
- 两个遗传簇在基因表达特征上不同,NNK-SMZL生存更差。
- 免疫微环境分免疫抑制型SMZL(50%病例,与炎症细胞和免疫检查点激活相关)和免疫沉默型SMZL(50%病例,与免疫排斥表型相关),具有不同突变和临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups and their underlying genomic abnormalities, pathway signatures, and microenvironment compositions to uncover biomarkers and therapeutic vulnerabilities. We studied 303 SMZL spleen samples collected through the IELSG46 multicenter international study (NCT02945319) by using a multiplatform approach. We carried out genetic and phenotypic analyses, defined self-organized signatures, validated the findings in independent primary tumor metadata and in genetically modified mouse models, and determined correlations with outcome data. We identified 2 prominent genetic clusters in SMZL, termed NNK (58% of cases, harboring NF-κB, NOTCH, and KLF2 modules) and DMT (32% of cases, with DNA-damage response, MAPK, and TLR modules). Genetic aberrations in multiple genes as well as cytogenetic and immunogenetic features distinguished NNK- from DMT-SMZLs. These genetic clusters not only have distinct underpinning biology, as judged by differences in gene-expression signatures, but also different outcomes, with inferior survival in NNK-SMZLs. Digital cytometry and in situ profiling segregated 2 basic types of SMZL immune microenvironments termed immune-suppressive SMZL (50% of cases, associated with inflammatory cells and immune checkpoint activation) and immune-silent SMZL (50% of cases, associated with an immune-excluded phenotype) with distinct mutational and clinical connotations. In summary, we propose a nosology of SMZL that can implement its classification and also aid in the development of rationally targeted treatments.
引用
- Bonfiglio F, Bruscaggin A, Guidetti F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022. PMID: 34653238. doi:10.1182/blood.2021012386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。